# US 2018/0022795 A1 · Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0022795 A1
- Document ID: US20180022795A1
- Status: Published application
- Kind: A1
- Application number: 15/658,115
- Filed: 2017-07-24
- Published: 2018-01-25
- Earliest claimed: 2013-03-15
- Assignees: Novartis AG; The Trustees of the University of Pennsylvania
- Applicants: Novartis AG; The Trustees of the University of Pennsylvania
- Inventors: Michael Milone; Enxiu Wang
- Web page: https://patentgrep.com/patent/US20180022795A1

## CPC

- C07K 16/18: against material from animals or humans
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/30: characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K 40/31: Chimeric antigen receptors [CAR]
- C07K 14/70503: {Immunoglobulin superfamily}
- C07K 14/70535: {Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)}
- A61K 2239/22: Intracellular domain
- A61K 2239/28: Expressing multiple CARs, TCRs or antigens
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K 2319/70: containing domain for protein-protein interaction
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides compositions and methods for regulating the specificity and activity of T cells. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “KIR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).

## Claims

### Claim at position 1

1-253. (canceled)

### Claim 254

A nucleic acid comprising a sequence encoding an activating killer cell immunoglobulin-like receptor chimeric antigen receptor (actKIR-CAR), wherein the actKIR-CAR comprises:
an extra-cellular antigen binding domain from an antibody molecule or a non-antibody scaffold;
an activating killer cell immunoglobulin-like receptor (actKIR) transmembrane domain; and
a cytoplasmic domain.

### Claim 255 (depends on 254)

The nucleic acid of claim 254, wherein the actKIR transmembrane domain can interact with the transmembrane domain of a DAP12 polypeptide.

### Claim 256 (depends on 254)

The nucleic acid of claim 254, wherein the actKIR transmembrane domain comprises a positively charged moiety.

### Claim 257 (depends on 254)

The nucleic acid of claim 254, wherein the cytoplasmic domain is a KIR-cytoplasmic domain.

### Claim 258 (depends on 254)

The nucleic acid of claim 254, wherein the antigen binding domain from an antibody molecule comprises a scFv.

### Claim 259 (depends on 254)

The nucleic acid of claim 254, wherein the actKIR-CAR further comprises an extracellular hinge domain.

### Claim 260 (depends on 254)

The nucleic acid of claim 254, wherein the actKIR-CAR further comprises an extracellular hinge domain that:
(i) is other than a KIR hinge domain;
(ii) is derived from a natural molecule;
(iii) comprises a non-naturally occurring polypeptide sequence;
(iv) is from human CD8-alpha subunit;
(v) is of less than 50, 20, or 10 amino acids in length, or
(vi) has fewer amino acids than a KIR2DS2 hinge domain.

### Claim 261 (depends on 254)

The nucleic acid of claim 254, wherein the actKIR-CAR comprises an actKIR cytoplasmic domain.

### Claim 262 (depends on 254)

The nucleic acid of claim 254, wherein the actKIR-CAR can interact with and promote signaling from an Immunoreceptor Tyrosine-based Activation Motif (ITAM)-containing polypeptide.

### Claim 263 (depends on 254)

The nucleic acid of claim 254, wherein the actKIR-CAR comprises a KIR D domain.

### Claim 264 (depends on 254)

The nucleic acid of claim 254, wherein the actKIR-CAR comprises a KIR D1 domain or a KIR D2 domain.

### Claim 265 (depends on 254)

The nucleic acid of claim 254, wherein the actKIR-CAR does not comprise a KIR D domain.

### Claim 266 (depends on 254)

The nucleic acid of claim 254, wherein the actKIR-CAR comprises a KIR2DS2 transmembrane domain or comprises a KIR2DS2 cytoplasmic domain.

### Claim 267 (depends on 254)

The nucleic acid of claim 254, wherein the actKIR-CAR can interact with and promote signaling from a DAP12 or DAP10 polypeptide.

### Claim 268 (depends on 254)

The nucleic acid of claim 254, wherein the actKIR-CAR can interact with and promote signaling from a DAP12 polypeptide.

### Claim 269 (depends on 254)

The nucleic acid of claim 254, wherein the antigen binding domain from an antibody molecule comprises an immunoglobulin single domain antibody (sdAb).

### Claim 270 (depends on 254)

The nucleic acid of claim 254, wherein the antigen binding domain from an antibody molecule comprises a single light chain variable domain (VL).

### Claim 271 (depends on 254)

The nucleic acid of claim 254, wherein the antigen binding domain from an antibody molecule comprises a single heavy chain variable domain (VH).

### Claim 272 (depends on 254)

The nucleic acid of claim 254, wherein the antigen binding domain from an antibody molecule comprises a nanobody.

### Claim 273 (depends on 254)

The nucleic acid of claim 254, wherein the antigen binding domain from an antibody molecule binds an antigen present on a cancer cell.

### Claim 274 (depends on 254)

The nucleic acid of claim 254, wherein the antigen binding domain from an antibody molecule binds an antigen present on a solid tumor cell.

### Claim 275 (depends on 254)

The nucleic acid of claim 254, wherein the antigen binding domain from an antibody molecule binds an antigen present on a hematological tumor cell.

### Claim 276 (depends on 254)

The nucleic acid of claim 254, wherein the antigen binding domain from an antibody molecule binds CD19, mesothelin, CD123, or BCMA.
